EUSA Pharma acquires global rights to Arcoral Tab from Arcoral Pharma

The product, Arcoral Tab, which EUSA plans to rebrand under the Caphosol name, is a topical oral agent used in the treatment of conditions resulting in reduced salivary flow such as xerostomia and hyposalivation caused by radiotherapy, mucositis, surgery, Sjögrens syndrome or obstruction of the salivary glands.

Arcoral Tab is characterized by high concentrations of calcium and phosphate ions, and lubricates the mucosa of the mouth, tongue and oropharynx and helps maintain the integrity of the oral cavity through its mineralizing potential. Arcoral Tab has the same active ingredients as Caphosol® but comes in the more convenient formulation of an effervescent tablet to produce the mouth rinse.

EUSA Pharma intends to promote Arcoral Tab directly through its specialist sales force in Europe, and through its international network of partners in a further 40 territories. EUSA also intends to submit the product for approval in the United States, and once approved to market it direct to specialists through the company’s established US commercial infrastructure.

"We are delighted to acquire the global rights to Arcoral Tab, which is an ideal strategic fit with our portfolio of specialty medicines, and our focus on oncology and oncology supportive care," said Lee Morley, EUSA Pharma’s Chief Executive Officer.

"This next generation formulation represents an important advance on our existing Caphosol product, and demonstrates EUSA’s commitment to introducing next generation treatments to help specialists meet their patients’ needs. As a recently established company, we have great ambitions for EUSA, and we look forward to accelerating our growth through the acquisition and in-licensing of further products that fit our specialty focus."

"EUSA Pharma, with its focus on oncology supportive care, is the perfect partner to ensure that patients across the world can benefit from our next generation formulation of Caphosol," said Bj?rn Johansen, Arcoral Pharma’s Chief Executive Officer.

"This advanced formulation is the result of many years of collaboration with scientists in Norway, Italy and the USA, and we now look forward to working with EUSA to make this important product available across the EU, US and further afield."